Cargando…

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

PURPOSE: Ridaforolimus is a non-prodrug mTOR inhibitor. The safety, pharmacokinetics (PK), and antitumor activity of oral ridaforolimus were assessed in Japanese patients with refractory solid tumors. METHODS: Ridaforolimus (20 or 40 mg) was administered as a single dose on Day 1, followed by once d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seki, Yoshitaka, Yamamoto, Noboru, Tamura, Yosuke, Goto, Yasushi, Shibata, Takashi, Tanioka, Maki, Asahina, Hajime, Nokihara, Hiroshi, Yamada, Yasuhide, Shimamoto, Takashi, Noguchi, Kazuo, Tamura, Tomohide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313018/ https://www.ncbi.nlm.nih.gov/pubmed/22143378 http://dx.doi.org/10.1007/s00280-011-1788-4

Ejemplares similares

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
por: Asahina, Hajime, et al.
Publicado: (2012)

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2011)

A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors
por: Nokihara, Hiroshi, et al.
Publicado: (2012)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Ridaforolimus
Publicado: (2012)

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
por: Wakui, Hiroshi, et al.
Publicado: (2014)

Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells
por: Morgan, Sherif S, et al.
Publicado: (2014)

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
por: Nakamichi, Shinji, et al.
Publicado: (2015)

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib
por: Koyama, Noriyuki, et al.
Publicado: (2014)

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer
por: Kanda, Shintaro, et al.
Publicado: (2020)

Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus
por: Keedy, Vicki L
Publicado: (2012)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

Pharmacokinetic Evaluation of a DSPE-PEG(2000) Micellar Formulation of Ridaforolimus in Rat
por: Remsberg, Connie M., et al.
Publicado: (2012)

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
por: Yamada, Kazuhiko, et al.
Publicado: (2010)

A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
por: Liu, Lian, et al.
Publicado: (2013)

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
por: Becker, Marc A., et al.
Publicado: (2016)

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
por: Pearson, Andrew D.J., et al.
Publicado: (2016)

Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
por: Seki, Yoshitaka, et al.
Publicado: (2018)

Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors
por: Yamamoto, Noboru, et al.
Publicado: (2009)

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors
por: Murakami, Haruyasu, et al.
Publicado: (2010)

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors
por: Ueda, Yutaka, et al.
Publicado: (2010)

New Insights into the Regulation of mTOR Signaling via Ca(2+)-Binding Proteins
por: Amemiya, Yuna, et al.
Publicado: (2023)

Decision-making by p53 and mTOR
por: Maki, Carl G.
Publicado: (2010)

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
por: Lush, Richard M., et al.
Publicado: (2012)

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
por: Chon, Hye Sook, et al.
Publicado: (2017)

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
por: Brana, I, et al.
Publicado: (2014)

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer
por: Yagishita, Shigehiro, et al.
Publicado: (2015)

Insulin Stimulation of Protein Synthesis and mTOR Signaling in Chick Myotube Cultures
por: Nakashima, Kazuki, et al.
Publicado: (2020)

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
por: Wei, Xiao X., et al.
Publicado: (2017)

Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma
por: Tamura, Yosuke, et al.
Publicado: (2015)

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
por: Colombo, N, et al.
Publicado: (2013)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
por: Carlo, Maria I., et al.
Publicado: (2016)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
por: Inoue, Kenichi, et al.
Publicado: (2016)

Autophagy and mTOR signaling during intervertebral disc aging and degeneration
por: Yurube, Takashi, et al.
Publicado: (2020)

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
por: Shimizu, Mikiko, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_kdqq5ui6a90cllfefbj9riehbf